Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Slides:



Advertisements
Similar presentations
Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer  Rita Nizzoli, PhD, Marcello Tiseo, MD, Francesco.
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer  Marcello Tiseo, MD, Marzia Capelletti,
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Localized Malignant Pleural Mesothelioma: Report of Two Cases
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L
Electronic Updates for JTO Readers
Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case?  Monica Giovannini, MD, Carmen.
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas  Lynette M. Sholl, MD, Stanislawa Weremowicz,
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.
Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung  Jos A. Stigt, MD, Nils A.
Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design  Arnaud Uguen, MD, Pascale Marcorelles,
A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review  Arianna Casagrande, MD, Federica Pederiva,
MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization  Serena Varesano, PhD, Sandra Salvi, PhD, Simona Boccardo, PhD, Jean.
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer  Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.
A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas  William.
Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity?  Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,
Erratum Journal of Thoracic Oncology
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.
Arnaud Uguen, MD, PhD  Journal of Thoracic Oncology 
Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer  Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.
Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method.
Mitotic Inhibitors Journal of Thoracic Oncology
A Translational View of the Molecular Pathogenesis of Lung Cancer
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma  Naoyuki.
Mirror Mirror on the Wall, Who Is the Fairest of Them All
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey  Daniel Morgensztern, MD, Shean Huey Ng,
Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer  Shengxiang Ren, MD, PhD, Fred.
Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent 
T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)
Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases  Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
Genetic Changes in Squamous Cell Lung Cancer: A Review
Ethnic Differences in the Management of Lung Cancer in New Zealand
Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report  Rafal Dziadziuszko, MD, PhD,
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed  D.
European Lung Cancer Conference (ELCC) 2016 Organisation
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia.
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
Who should decide margin length in pulmonary excision of lung cancer?
ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material  Eugen C. Minca, MD, PhD, Christopher P. Lanigan,
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure  Joel P. Womack,
ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer  Benjamin Solomon, MBBS, PhD, Marileila.
A Review of First-Line Treatment for Small-cell Lung Cancer
Mark A. Socinski, MD  Journal of Thoracic Oncology 
Robert Comis, MD, The Passing of a “Lung Man”
Ana Luque, MD, Edurne Arriola, MD, PhD  Journal of Thoracic Oncology 
Presentation transcript:

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza Lagrasta, PhD, Rita Nizzoli, PhD, Annamaria Guazzi, PhD, Gallia Graiani, PhD, Guido Rindi, MD, Andrea Ardizzoni, MD  Journal of Thoracic Oncology  Volume 5, Issue 4, Pages 551-553 (April 2010) DOI: 10.1097/JTO.0b013e3181ce3b28 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Dual-color fluorescence in situ hybridization assays using epidermal growth factor receptor (red)/CEP7 (green) probe (Vysis, Downers Grove, IL) in cytologic specimens: disomy (A), high polysomy (B), and gene amplification (C). Journal of Thoracic Oncology 2010 5, 551-553DOI: (10.1097/JTO.0b013e3181ce3b28) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.